A F Hezel, M S Noel, J N Allen, T A Abrams, M Yurgelun, J E Faris, L Goyal, J W Clark, L S Blaszkowsky, J E Murphy, H Zheng, A A Khorana, G C Connolly, O Hyrien, A Baran, M Herr, K Ng, S Sheehan, D J Harris, E Regan, D R Borger, A J Iafrate, C Fuchs, D P Ryan, A X Zhu
BACKGROUND: Current data suggest that platinum-based combination therapy is the standard first-line treatment for biliary tract cancer. EGFR inhibition has proven beneficial across a number of gastrointestinal malignancies; and has shown specific advantages among KRAS wild-type genetic subtypes of colon cancer. We report the combination of panitumumab with gemcitabine (GEM) and oxaliplatin (OX) as first-line therapy for KRAS wild-type biliary tract cancer. METHODS: Patients with histologically confirmed, previously untreated, unresectable or metastatic KRAS wild-type biliary tract or gallbladder adenocarcinoma with ECOG performance status 0-2 were treated with panitumumab 6 mg kg(-1), GEM 1000 mg m(-2) (10 mg m(-2) min(-1)) and OX 85 mg m(-2) on days 1 and 15 of each 28-day cycle...
July 29, 2014: British Journal of Cancer